Surmodics (NASDAQ:SRDX) Receives "Market Perform" Rating from Barrington Research

Key Points

• Surmodics (NASDAQ:SRDX) received a "market perform" rating from Barrington Research, while Needham & Company LLC reaffirmed a "hold" rating for the stock.
• The company reported a quarterly earnings per share (EPS) of $0.06, surpassing the consensus estimate of ($0.21), and had revenues of $29.57 million for the quarter.
• Institutional investors hold 96.63% of Surmodics' stock, with significant recent investments from firms such as Creative Planning and Thompson Davis & CO. Inc.

Barrington Research reissued their market perform rating on shares of Surmodics (NASDAQ:SRDX - Free Report) in a research report report published on Monday morning,Benzinga reports. Barrington Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.30) EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.00 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at ($0.12) EPS.

Separately, Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a research report on Wednesday, April 30th.

Surmodics Trading Up 0.9%

SRDX stock traded up $0.36 during midday trading on Monday, hitting $38.00. The company had a trading volume of 170,910 shares, compared to its average volume of 179,352. The company has a current ratio of 3.91, a quick ratio of 3.10 and a debt-to-equity ratio of 0.27. The stock has a market cap of $543.33 million, a price-to-earnings ratio of -30.89 and a beta of 1.31. The stock's 50 day moving average price is $31.92 and its 200 day moving average price is $30.87. Surmodics has a 52 week low of $26.00 and a 52 week high of $40.38.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.27. Surmodics had a negative return on equity of 2.99% and a negative net margin of 14.59%. The company had revenue of $29.57 million during the quarter, compared to the consensus estimate of $28.04 million. As a group, equities research analysts expect that Surmodics will post 0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Surmodics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its stake in shares of Surmodics by 705.9% in the second quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company's stock worth $37,000 after purchasing an additional 1,080 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Surmodics by 67.6% in the second quarter. BNP Paribas Financial Markets now owns 1,435 shares of the company's stock valued at $43,000 after purchasing an additional 579 shares during the period. Strs Ohio acquired a new stake in Surmodics in the first quarter valued at approximately $122,000. Legal & General Group Plc grew its holdings in Surmodics by 34.2% in the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock valued at $137,000 after purchasing an additional 880 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Surmodics in the fourth quarter valued at approximately $217,000. 96.63% of the stock is currently owned by hedge funds and other institutional investors.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).